SYS-CON MEDIA Authors: Liz McMillan, Carmen Gonzalez, Zakia Bouachraoui, Roger Strukhoff, David Linthicum

News Feed Item

ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent

RANCHO CORDOVA, Calif., Sept. 12, 2011 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells in the practice of regenerative medicine, reported results for the fourth quarter and all of fiscal 2011.

For the quarter ended June 30, 2011, the Company reported revenues of $5.4 million, compared to $7.2 million in the fourth quarter a year ago and $5.2 million in the prior quarter. Disposable sales in the fourth quarter of fiscal 2011 were $3.0 million, compared with $4.8 million in the same period a year ago and $3.0 million in the prior quarter. ThermoGenesis reported a net loss of $1.2 million, or $0.07 per share, in the fourth quarter of 2011, versus a net loss of $171,000, or $0.01 per share, in the same period a year ago.

For fiscal 2011, ThermoGenesis reported sales of $23.4 million compared with revenues of $23.1 million in fiscal 2010. Disposable sales in fiscal 2011 were $13.8 million, compared with $14.3 million for fiscal 2010. The Company reported a net loss of $2.6 million, or $0.17 per share, compared with a net loss of $5.2 million, or $0.37 per share, in fiscal 2010. The Company ended fiscal 2011 with $12.3 million in cash and cash equivalents versus $13.5 million at the end of the third quarter of 2011 and $10.7 million at the end of fiscal 2010. Backlog at the end of fiscal 2011 was $1.1 million.

"We are pleased to report a $2.6 million reduction in our annual net loss, or an improvement of 51 percent versus 2010. We accomplished this despite nominal growth in revenues year-over-year. We realized measurable improvements in gross margins due to operating efficiencies and lower supplier costs, and a more than $1 million decline in operating expenses. Our performance for the quarter reflected the continued softness in the U.S. and European cord blood markets. This was partially offset by an increase in Res-Q® (Res-Q) System disposable revenues," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.

"During the quarter, we achieved two important milestones in our program to increase the market presence for our Res-Q technology. These included FDA clearance of our 510(k) submission for the preparation of autologous platelet rich plasma (PRP), and the commercial launch of Res-Q for bone marrow indications in India. Also during the quarter, we made an initial shipment of AXP® AutoXpress(TM) Platform (AXP) and disposables to our Latin American distributor, which are being placed with customers in Mexico and Brazil," he stated.

"Despite a challenging market environment, fiscal 2011 was marked by a number of major accomplishments, particularly our increased presence in China where we have a number of distributor and customer relationships with leading regenerative medicine companies. We also initiated several clinical evaluations for our products, including studies involving Res-Q in China and India. With respect to our financial performance, we realized continued improvement in gross margins and operating expense levels, and strengthened our balance sheet by raising approximately $4 million of growth capital through an offering of stock and warrants," Engle noted.

"We are looking forward to achieving other key milestones in our long-term growth strategy during fiscal 2012. There is growing interest in our cord blood and bone marrow technologies, particularly in important international markets where we have strong partnerships with market leaders. Our plan is to leverage these strong technology assets for adoption in a wider range of indications, through the development of new products and strategic partnerships and joint ventures. At the same time, we will continue to position the company for profitability, while maintaining a strong balance sheet to support our initiatives," he added.

The Company said that it expects revenues for the first two quarters of fiscal 2012 will be relatively consistent with those of the fourth quarter 2011.

Company's Conference Call and Webcast

Management will hold a conference call today at 2 p.m., Pacific (5 p.m., Eastern) to review the fiscal 2011 fourth quarter results.

Conference call details:


    Dial-in (U.S.):                     1-800-860-2442
    Dial-in (Internationally):          1-412-858-4600
    Conference Name:                    "ThermoGenesis"


To listen to the audio webcast of the call during or after the event, please visit

http://www.thermogenesis.com/investors-webcasts-and-calls.aspx

An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days.

To access the replay:


    Access number (U.S.):               1-877-344-7529
    Access number
     (Internationally)                  1-412-317-0088
    Conference ID#:                                 385107


About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress(TM) Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP(TM) MarrowXpress(TM) and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q® 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2011 and 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011 and 2012. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
[email protected]

                     THERMOGENESIS CORP.
            Condensed Consolidated Balance Sheets
                         (Unaudited)

                                         June 30,         June 30,
                                         --------         --------
                                               2011             2010
                                               ----             ----
    ASSETS
    Current assets:
      Cash and cash equivalents         $12,309,000      $10,731,000
      Accounts receivable, net            3,963,000        6,095,000
      Inventories                         6,348,000        5,034,000
      Other current assets                  420,000          301,000
                                            -------          -------

       Total current assets              23,040,000       22,161,000

      Equipment, net                      1,310,000        1,701,000
      Other assets                           49,000          168,000
                                             ------          -------

                                        $24,399,000      $24,030,000
                                        ===========      ===========

    LIABILITIES AND STOCKHOLDERS'
     EQUITY

    Current liabilities:
      Accounts payable                   $1,791,000       $2,383,000
      Other current liabilities           2,273,000        3,191,000
                                          ---------        ---------

       Total current liabilities          4,064,000        5,574,000

    Long-term liabilities                   242,000          677,000

    Stockholders' equity                 20,093,000       17,779,000
                                         ----------       ----------

                                        $24,399,000      $24,030,000
                                        ===========      ===========


                               THERMOGENESIS CORP.
                 Condensed Consolidated Statements of Operations
                                   (Unaudited)

                      Three Months Ended           Year Ended
                           June 30,                 June 30,
                             2011          2010         2011         2010
                             ----          ----         ----         ----
    Net revenues       $5,378,000    $7,176,000  $23,400,000  $23,088,000

    Cost of
     revenues           3,512,000     4,700,000   14,563,000   15,643,000
                        ---------     ---------   ----------   ----------

       Gross profit     1,866,000     2,476,000    8,837,000    7,445,000
                        ---------     ---------    ---------    ---------

    Expenses:
      Selling,
       general and
       administrative   2,245,000     1,711,000    8,669,000    7,686,000

      Research and
       development        789,000       939,000    3,003,000    5,013,000
                          -------       -------    ---------    ---------

        Total
         operating
         expenses       3,034,000     2,650,000   11,672,000   12,699,000

    Interest and
     other income,
     net                       --         3,000      268,000       61,000
                              ---         -----      -------       ------

    Net loss          ($1,168,000)    ($171,000) ($2,567,000) ($5,193,000)
                      ===========     =========  ===========  ===========

    Basic and
     diluted net
     loss per
     common                ($0.07)       ($0.01)      ($0.17)      ($0.37)
      share                ======        ======       ======       ======

    Shares used in
     computing per
     share data        16,346,366    14,023,240   14,816,163   14,023,240
                       ==========    ==========   ==========   ==========


                       THERMOGENESIS CORP.
         Condensed Consolidated Statements of Cash Flows
                           (Unaudited)

                                                     Year Ended
                                                      June 30,
                                                    2011               2010
                                                    ----               ----
    Cash flows from operating
     activities:
      Net loss                               ($2,567,000)       ($5,193,000)
      Adjustments to reconcile net loss
       to net cash used
       in operating activities:
       Depreciation and amortization             466,000            492,000
       Stock based compensation expense          960,000            518,000
       Loss on sale/retirement of
        equipment                                 13,000                 --
      Loss on impairment of equipment             65,000             26,000
       Accretion of discount on short-
        term investments                              --             (2,000)

       Net change in operating assets and
        liabilities:
        Accounts receivable, net               2,132,000         (1,797,000)
         Inventories                          (1,338,000)            34,000
        Other current assets                       1,000            361,000
         Other assets                            119,000             79,000
         Accounts payable                       (592,000)           602,000
         Accrued payroll and related
          expenses                                75,000           (572,000)
         Deferred revenue                       (604,000)          (132,000)
         Other liabilities                      (822,000)         1,156,000
                                                --------          ---------
       Net cash used in operating
        activities                            (2,092,000)        (4,428,000)
                                              ----------         ----------

    Cash flows from investing
     activities:
      Capital expenditures                      (266,000)          (470,000)
       Proceeds from sale of equipment            17,000         (6,741,000)
      Maturities of investments                       --         15,719,000
                                                     ---         ----------
       Net cash (used in)/provided by
        investing activities:                   (249,000)         8,508,000
                                                --------          ---------

    Cash flows from financing
     activities:
       Exercise of stock options                   7,000                 --
       Issuance of common stock                3,914,000                 --
      Payments on capital lease
       obligations                                (2,000)            (4,000)
                                                  ------             ------
       Net cash provided by/(used in)
        financing activities                   3,919,000             (4,000)
                                               ---------             ------
    Net increase/(decrease) in cash
     and cash equivalents                      1,578,000          4,076,000
    Cash and cash equivalents at
     beginning of period                      10,731,000          6,655,000
                                              ----------          ---------
    Cash and cash equivalents at end
     of period                               $12,309,000        $10,731,000
                                             ===========        ===========


SOURCE ThermoGenesis Corp.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected pat...
There are many examples of disruption in consumer space – Uber disrupting the cab industry, Airbnb disrupting the hospitality industry and so on; but have you wondered who is disrupting support and operations? AISERA helps make businesses and customers successful by offering consumer-like user experience for support and operations. We have built the world’s first AI-driven IT / HR / Cloud / Customer Support and Operations solution.
ScaleMP is presenting at CloudEXPO 2019, held June 24-26 in Santa Clara, and we’d love to see you there. At the conference, we’ll demonstrate how ScaleMP is solving one of the most vexing challenges for cloud — memory cost and limit of scale — and how our innovative vSMP MemoryONE solution provides affordable larger server memory for the private and public cloud. Please visit us at Booth No. 519 to connect with our experts and learn more about vSMP MemoryONE and how it is already serving some of...
Darktrace is the world's leading AI company for cyber security. Created by mathematicians from the University of Cambridge, Darktrace's Enterprise Immune System is the first non-consumer application of machine learning to work at scale, across all network types, from physical, virtualized, and cloud, through to IoT and industrial control systems. Installed as a self-configuring cyber defense platform, Darktrace continuously learns what is ‘normal' for all devices and users, updating its understa...
Codete accelerates their clients growth through technological expertise and experience. Codite team works with organizations to meet the challenges that digitalization presents. Their clients include digital start-ups as well as established enterprises in the IT industry. To stay competitive in a highly innovative IT industry, strong R&D departments and bold spin-off initiatives is a must. Codete Data Science and Software Architects teams help corporate clients to stay up to date with the mod...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
Platform9, the leader in SaaS-managed hybrid cloud, has announced it will present five sessions at four upcoming industry conferences in June: BCS in London, DevOpsCon in Berlin, HPE Discover and Cloud Computing Expo 2019.
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
When you're operating multiple services in production, building out forensics tools such as monitoring and observability becomes essential. Unfortunately, it is a real challenge balancing priorities between building new features and tools to help pinpoint root causes. Linkerd provides many of the tools you need to tame the chaos of operating microservices in a cloud native world. Because Linkerd is a transparent proxy that runs alongside your application, there are no code changes required. I...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Druva is the global leader in Cloud Data Protection and Management, delivering the industry's first data management-as-a-service solution that aggregates data from endpoints, servers and cloud applications and leverages the public cloud to offer a single pane of glass to enable data protection, governance and intelligence-dramatically increasing the availability and visibility of business critical information, while reducing the risk, cost and complexity of managing and protecting it. Druva's...
Kubernetes as a Container Platform is becoming a de facto for every enterprise. In my interactions with enterprises adopting container platform, I come across common questions: - How does application security work on this platform? What all do I need to secure? - How do I implement security in pipelines? - What about vulnerabilities discovered at a later point in time? - What are newer technologies like Istio Service Mesh bring to table?In this session, I will be addressing these commonly asked ...
BMC has unmatched experience in IT management, supporting 92 of the Forbes Global 100, and earning recognition as an ITSM Gartner Magic Quadrant Leader for five years running. Our solutions offer speed, agility, and efficiency to tackle business challenges in the areas of service management, automation, operations, and the mainframe.